3 citations
,
May 2023 in “Current Molecular Medicine” This review discusses the distinction between platelet-rich plasma and stem cell-based therapies in regenerative medicine, highlighting their different roles and stressing the importance of honest representation by commercial and health entities.
This study identified CD28 as a promising drug target for treating alopecia areata, using a multi-omics approach to highlight its role in immune regulation and linking it to favorable safety profiles, thus offering a strategy for autoimmune target discovery.
This study identified CD28 as a potential drug target in treating alopecia areata by linking immune signaling pathways to local inflammation, highlighting belatacept as a promising treatment option due to minimal adverse effects and providing insights into autoimmune target discovery.
March 2026 in “Skin Appendage Disorders” This study identified CD28, GZMB, and CD1C as key immune regulators in alopecia areata, highlighting CD28 as a potential therapeutic target with a promising safety profile, using a proteome-anchored multi-omics approach to uncover actionable targets for this autoimmune hair-loss disorder.
1 citations
,
April 2025 in “Journal of Feline Medicine and Surgery” In this review, the authors discussed the clinical presentations and management of feline immune-mediated skin diseases such as erythema multiforme and Stevens-Johnson syndrome, noting that although these conditions are rare, they can severely affect cats' quality of life.
